Bicara Therapeutics Inc. (BCAX) EBITDA

Annual EBITDA:

-$82.33M-$42.46M(-106.50%)
December 31, 2024

Summary

  • As of today, BCAX annual EBITDA is -$82.33 million, with the most recent change of -$42.46 million (-106.50%) on December 31, 2024.
  • During the last 3 years, BCAX annual EBITDA has fallen by -$44.61 million (-118.26%).
  • BCAX annual EBITDA is now -118.26% below its all-time high of -$37.72 million, reached on December 31, 2022.

Performance

1-Year Change

-106.5%

3-Year Change

-118.26%

5-Year Change

-118.26%

15-Year Change

-118.26%

BCAX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

20.35%
BCAX annual EBITDA is higher than 20.35% of companies in Healthcare sector

Range

All-Time High

-$37.72M
BCAX annual EBITDA is currently -118.26% below its historical high of -$37.72 million

3-Year Low

-$82.33M
BCAX annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
BCAX previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

Mar 26, 2026
BCAX next annual earnings announcement is scheduled for Mar 26, 2026

OtherBCAXincome statement metrics

Annual Revenue

$0.00
BCAX annual revenue is $0.00

Annual Net Income

-$68.00M
BCAX annual net profit is -$68.00 million

Annual EBIT

-$82.39M
BCAX annual earnings before interest & taxes is -$82.39 million

Annual EPS

-$1.25
BCAX annual earnings per share is -$1.25

Quarterly EBITDA:

-$40.65M-$8.65M(-27.04%)
September 30, 2025

Summary

  • As of today, BCAX quarterly EBITDA is -$40.65 million, with the most recent change of -$8.65 million (-27.04%) on September 30, 2025.
  • Over the past year, BCAX quarterly EBITDA has dropped by -$20.04 million (-97.22%).
  • BCAX quarterly EBITDA is now -326.66% below its all-time high of -$9.53 million, reached on September 1, 2023.

Performance

3-Month Change

-27.04%

1-Year Change

-97.22%

3-Year Change

-326.66%

5-Year Change

-326.66%

BCAX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

10.22%
BCAX quarterly EBITDA is higher than 10.22% of companies in Healthcare sector

Range

All-Time High

-$9.53M
BCAX quarterly EBITDA is currently -326.66% below its historical high of -$9.53 million

3-Year Low

-$41.77M
BCAX quarterly EBITDA is currently +2.67% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2025
BCAX previous earnings announcement was published on Sep 30, 2025

Next Quarterly Earnings Report Date

Mar 26, 2026
BCAX next earnings announcement is scheduled for Mar 26, 2026

OtherBCAXincome statement metrics

Quarterly Revenue

$0.00
BCAX quarterly revenue is $0.00

Quarterly Net Income

-$36.33M
BCAX quarterly net profit is -$36.33 million

Quarterly EBIT

-$40.68M
BCAX quarterly earnings before interest & taxes is -$40.68 million

Quarterly EPS

-$0.67
BCAX quarterly earnings per share is -$0.67

TTM EBITDA:

-$141.04M-$20.04M(-16.56%)
September 30, 2025

Summary

  • As of today, BCAX TTM EBITDA is -$141.04 million, with the most recent change of -$20.04 million (-16.56%) on September 30, 2025.
  • Over the past year, BCAX TTM EBITDA has dropped by -$85.33 million (-153.17%).
  • BCAX TTM EBITDA is now -1380.29% below its all-time high of -$9.53 million, reached on September 1, 2023.

Performance

3-Month Change

-16.56%

1-Year Change

-153.17%

3-Year Change

-1380.29%

5-Year Change

-1380.29%

BCAX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

11.47%
BCAX TTM EBITDA is higher than 11.47% of companies in Healthcare sector

Range

All-Time High

-$9.53M
BCAX TTM EBITDA is currently -1380.29% below its historical high of -$9.53 million

3-Year Low

-$141.04M
BCAX TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2025
BCAX previous earnings announcement was published on Sep 30, 2025

Next Quarterly Earnings Report Date

Mar 26, 2026
BCAX next earnings announcement is scheduled for Mar 26, 2026

OtherBCAXincome statement metrics

TTM Revenue

$0.00
BCAX TTM revenue is $0.00

TTM Net Income

-$121.52M
BCAX TTM net profit is -$121.52 million

TTM EBIT

-$141.12M
BCAX TTM earnings before interest & taxes is -$141.12 million

TTM EPS

-$2.23
BCAX TTM earnings per share is -$2.23

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$82.33M
BCAX annual EBITDA is -$82.33 million

Annual Net Income

-$68.00M
BCAX annual net profit is -$68.00 million

Annual Interest Expense

$0.00
BCAX annual interest expense is $0.00

Annual Income Tax

$187.00K
BCAX annual income tax is $187.00 thousand

Annual D&A

$56.00K
BCAX annual D&A is $56.00 thousand

BCAX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-106.5%-97.2%-153.2%
3Y3 Years-118.3%-326.7%-1380.3%
5Y5 Years-118.3%-326.7%-1380.3%

BCAX EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-118.3%at low-326.7%+2.7%-1380.3%at low
5Y5-Year-118.3%at low-326.7%+2.7%-1380.3%at low
All-TimeAll-Time-118.3%at low-326.7%+2.7%-1380.3%at low

BCAX EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$40.65M(-27.0%)
-$141.04M(-16.6%)
Jun 2025
-
-$32.00M(+23.4%)
-$121.00M(-11.3%)
Mar 2025
-
-$41.77M(-56.9%)
-$108.74M(-32.1%)
Dec 2024
-$82.33M
-$26.62M(-29.2%)
-$82.33M(-47.8%)
Sep 2024
-
-$20.61M(-4.4%)
-$55.71M(-24.8%)
DateAnnualQuarterlyTTM
Jun 2024
-
-$19.74M(-28.5%)
-$44.63M(-79.3%)
Mar 2024
-
-$15.36M(-61.2%)
-$24.89M(-161.2%)
Dec 2023
-$39.87M(-5.7%)
-
-
Sep 2023
-
-$9.53M
-$9.53M
Dec 2022
-$37.72M
-
-

FAQ

  • What is Bicara Therapeutics Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Bicara Therapeutics Inc.?
  • What is Bicara Therapeutics Inc. annual EBITDA year-on-year change?
  • What is Bicara Therapeutics Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Bicara Therapeutics Inc.?
  • What is Bicara Therapeutics Inc. quarterly EBITDA year-on-year change?
  • What is Bicara Therapeutics Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Bicara Therapeutics Inc.?
  • What is Bicara Therapeutics Inc. TTM EBITDA year-on-year change?

What is Bicara Therapeutics Inc. annual EBITDA?

The current annual EBITDA of BCAX is -$82.33M

What is the all-time high annual EBITDA for Bicara Therapeutics Inc.?

Bicara Therapeutics Inc. all-time high annual EBITDA is -$37.72M

What is Bicara Therapeutics Inc. annual EBITDA year-on-year change?

Over the past year, BCAX annual EBITDA has changed by -$42.46M (-106.50%)

What is Bicara Therapeutics Inc. quarterly EBITDA?

The current quarterly EBITDA of BCAX is -$40.65M

What is the all-time high quarterly EBITDA for Bicara Therapeutics Inc.?

Bicara Therapeutics Inc. all-time high quarterly EBITDA is -$9.53M

What is Bicara Therapeutics Inc. quarterly EBITDA year-on-year change?

Over the past year, BCAX quarterly EBITDA has changed by -$20.04M (-97.22%)

What is Bicara Therapeutics Inc. TTM EBITDA?

The current TTM EBITDA of BCAX is -$141.04M

What is the all-time high TTM EBITDA for Bicara Therapeutics Inc.?

Bicara Therapeutics Inc. all-time high TTM EBITDA is -$9.53M

What is Bicara Therapeutics Inc. TTM EBITDA year-on-year change?

Over the past year, BCAX TTM EBITDA has changed by -$85.33M (-153.17%)
On this page